The race is on for coronavirus vaccines and treatments: current R&D status
Since the first reports of coronavirus (COVID-19) in Wuhan, China in December 2019 there have been more than 823,000 confirmed cases and over 45,000 deaths in 206 countries worldwide.
More than ever before pharma, biotechs, start-ups, research institutes and universities are working together to develop vaccinations and to identify new therapies to treat the symptoms of this contagious disease.
Vaccination strategies
According to the World Health Organisation (WHO) 35 vaccines are in development against COVID-19 (Table 1). Companies have adopted a variety of approaches including the use of DNA and RNA platforms, inactivated or attenuated viruses, non-replicating viral vectors and protein subunits. The first two vaccines have entered clinical development:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze